Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Felodipine

FDA-approved product (tablet, extended release, oral), marketed as Felodipine, Plendil.

Registered studies
28
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Felodipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Diabetes mellitus
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

28registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Felodipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Felodipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina

    NCT00507845 · start 2007-06

    Registered record
    Registry ID
    NCT00507845
    Conditions
    Hypertension
    Interventions
    Ramipril-Felodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    Not recorded
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionRamipril-Felodipine
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients

    NCT00392262 · start 2006-08

    Registered record
    Registry ID
    NCT00392262
    Conditions
    Hypertension
    Interventions
    valsartan + amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-02
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionvalsartan + amlodipine
    PhasePhase 3
    Registry statusCompleted

  • Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

    NCT00348686 · start 2006-06

    Registered record
    Registry ID
    NCT00348686
    Conditions
    Hypertension; Left Ventricular Hypertrophy
    Interventions
    Candesartan; Candesartan; Felodipine; Felodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-06
    Completion
    2008-06
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Left Ventricular Hypertrophy
    InterventionCandesartan; Candesartan; Felodipine; Felodipine
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine

    NCT00367939 · start 2005-12

    Registered record
    Registry ID
    NCT00367939
    Conditions
    Hypertension
    Interventions
    valsartan + amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-07
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionvalsartan + amlodipine
    PhasePhase 3
    Registry statusCompleted

  • The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.

    NCT02336607 · start 2005-12

    Registered record
    Registry ID
    NCT02336607
    Conditions
    Hypertension
    Interventions
    Felodipine tablet (Plendil) alone; Felodipine tablet (Plendil)+Hydrochlorothiazide; Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK); Felodipine tablets (Plendil)+Lisinopril (Zestril)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-08
    Enrolment
    529

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionFelodipine tablet (Plendil) alone; Felodipine tablet (Plendil)+Hydrochlorothiazide; Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK); Felodipine tablets (Plendil)+Lisinopril (Zestril)
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension

    NCT00861016 · start 2005-10

    Registered record
    Registry ID
    NCT00861016
    Conditions
    Hypertension
    Interventions
    metoprolol succinate prolonged-release tablet and felodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-05
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionmetoprolol succinate prolonged-release tablet and felodipine
    PhasePhase 4
    Registry statusCompleted

  • Hypertension in Hemodialysis Patients (Aim 3)

    NCT00582114 · start 2005-08

    Registered record
    Registry ID
    NCT00582114
    Conditions
    Hemodialysis; Hypertension; Left Ventricular Hypertrophy
    Interventions
    Lisinopril; Atenolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-08
    Completion
    2013-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis; Hypertension; Left Ventricular Hypertrophy
    InterventionLisinopril; Atenolol
    PhasePhase 3
    Registry statusTerminated

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

    NCT00679653 · start 2002-02

    Registered record
    Registry ID
    NCT00679653
    Conditions
    Obesity; Hypertension
    Interventions
    sibutramine; sibutramine; verapamil/trandolapril; metoprolol/HCT; felodipine/ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-02
    Completion
    Not recorded
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Hypertension
    Interventionsibutramine; sibutramine; verapamil/trandolapril; metoprolol/HCT +1 more
    PhasePhase 3
    Registry statusCompleted

  • Action to Control Cardiovascular Risk in Diabetes (ACCORD)

    NCT00000620 · start 1999-09

    Registered record
    Registry ID
    NCT00000620
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease
    Interventions
    Anti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-09
    Completion
    2012-12
    Enrolment
    10,251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension +3 more
    InterventionAnti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    PhasePhase 3
    Registry statusCompleted

  • Felodipine Event Reduction Study

    NCT01136863 · start 1998-04

    Registered record
    Registry ID
    NCT01136863
    Conditions
    Hypertension
    Interventions
    Felodipine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1998-04
    Completion
    2004-06
    Enrolment
    9,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionFelodipine; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition

    NCT01630655

    Registered record
    Registry ID
    NCT01630655
    Conditions
    Healthy
    Interventions
    Torrent's Felodipine Extended-Release Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTorrent's Felodipine Extended-Release Tablets
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition

    NCT01630902

    Registered record
    Registry ID
    NCT01630902
    Conditions
    Healthy
    Interventions
    Torrent's Felodipine Extended-Release Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTorrent's Felodipine Extended-Release Tablets
    PhasePhase 1
    Registry statusCompleted